Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | DHFR | P00374 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251060 | 0.94 | KDM4E (0.63) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL8349049 | 0.93 | TSHR (0.65) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL9974699 | 0.93 | TSHR (0.65) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL59488 | 0.90 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL15295402 | 0.90 | ALDH1A1 (0.65) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL720798 | 0.89 | CYP2D6 (0.58) | TSHRDHFRLTA4HGGPS1PLA2G4B | |
| SCHEMBL14382693 | 0.87 | CYP2D6 (0.57) | TSHRDHFRLTA4HGGPS1PLA2G4B | |
| SCHEMBL4397448 | 0.86 | TSHR (0.63) | SMN1; SMN2MAPK1TSHRLTA4HPLA2G4B | |
| SCHEMBL6468919 | 0.85 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL10272584 | 0.85 | KDM4E (0.70) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023102378-A1 | MACROCYCLIC COMPOUNDS HAVING FARNESYLTRANSFERASE INHIBITORY ACTIVITY | KURA ONCOLOGY, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20170348258-A1 | 3-Amino Benzamide Derivative Serving As B-Lactam Auxiliary Antibiotic, Preparation Method and Use Thereof | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2017-12-07 | — | — | US | disclosed |
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-15 | — | — | US | disclosed |
| US-20130045952-A1 | ABA Receptor Agonists for Increased Plant Stress Resistance | VAN ANDEL RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2013-01-17 | — | — | US | disclosed |
| US-7999139-B2 | Solid-phase preparation of [18F]fluorohaloalkanes | HAMMERSMITH IMANET LIMITED (GB) | 2011-08-16 | — | — | US | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-7504208-B2 | Solid-phase fluorination of uracil and cytosine | HAMMERSMITH IMANET LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20070202039-A1 | Solid-Phase Preparation of [18F]Fluorohaloalkanes | HAMMERSMITH IMANET LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-7223891-B2 | Solid-phase preparation of [18F] fluorohaloalkanes | HAMMERSMITH IMANET LTD. (GB) | 2007-05-29 | — | — | US | disclosed |
| WO-2007042660-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
| US-7196080-B2 | Respiratory system disordeers; chronic obstructive pulminary disease | ASTELLAS PHARMA INC. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-4459186-A | Electrochemical oxidation of alkyl aromatic compounds | UOP INC. (US) | 1984-07-10 | — | — | US | disclosed |
| US-4212711-A | Electrochemical oxidation of alkyl aromatic compounds | UOP INC. (US) | 1980-07-15 | — | — | US | disclosed |
| US-4212710-A | Electrochemical oxidation of alkyl aromatic compounds | UOP INC. (US) | 1980-07-15 | — | — | US | disclosed |
| US-4148696-A | Electrochemical oxidation of activated alkyl aromatic compounds | UOP INC. (US) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | KDM4E 2635/4885ALDH1A1 4776/4885SMN1; SMN2 4701/4885 |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | KDM4E 3641/4885ALDH1A1 1978/4885SMN1; SMN2 3807/4885 |
| US-20170348258-A1 | 3-Amino Benzamide Derivative Serving As B-Lactam Auxiliary Antibiotic, Preparation Method and Use Thereof | BCAT2, SBDS, BCAT1 | KDM4E 1472/4885ALDH1A1 2169/4885SMN1; SMN2 2209/4885 |
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | POLRMT, POLR1C, FBL | KDM4E 2085/4885ALDH1A1 1785/4885SMN1; SMN2 3912/4885 |
| US-20130045952-A1 | ABA Receptor Agonists for Increased Plant Stress Resistance | BROX, AAK1, ADORA3 | KDM4E 3079/4885ALDH1A1 3422/4885SMN1; SMN2 4877/4885 |
| US-20070202039-A1 | Solid-Phase Preparation of [18F]Fluorohaloalkanes | SLCO2B1, SLCO2A1, FES | KDM4E 2270/4885ALDH1A1 2599/4885SMN1; SMN2 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.